In situ assembly of enzyme inhibitors using extended tethering

Abstract

Cysteine aspartyl protease-3 (caspase-3) is a mediator of apoptosis and a therapeutic target for a wide range of diseases. Using a dynamic combinatorial technology, 'extended tethering', we identified unique nonpeptidic inhibitors for this enzyme. Extended tethering allowed the identification of ligands that bind to discrete regions of caspase-3 and also helped direct the assembly of these ligands into small-molecule inhibitors. We first designed a small-molecule 'extender' that irreversibly alkylates the cysteine residue of caspase-3 and also contains a thiol group. The modified protein was then screened against a library of disulfide-containing small-molecule fragments. Mass-spectrometry was used to identify ligands that bind noncovalently to the protein and that also form a disulfide linkage with the extender. Linking the selected fragments with binding elements from the extenders generates reversible, tight-binding molecules that are druglike and distinct from known inhibitors. One molecule derived from this approach inhibited apoptosis in cells.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2: Extended tethering identifies small chemical fragments.
Figure 3: X-ray crystal structures of caspase-3 in complex with various ligands.
Figure 4: Evolution of selected fragments into reversible inhibitors of caspase-3.
Figure 5: Compound 7 inhibits Fas-induced apoptosis in Jurkat cells.

Accession codes

Accessions

Protein Data Bank

References

  1. 1

    McGovern, S.L., Caselli, E., Grigorieff, N. & Shoichet, B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712–1722 (2002).

  2. 2

    Huc, I. & Lehn, J.M. Virtual combinatorial libraries: dynamic generation of molecular and supramolecular diversity by self-assembly. Proc. Natl. Acad. Sci. USA 94, 2106–2110 (1997).

  3. 3

    Lehn, J.M. & Eliseev, A. Dynamic combinatorial chemistry. Science 291, 2331–2332 (2001).

  4. 4

    Nicolaou, K.C. et al. Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis. Chem. Eur. J. 7, 3824–3843 (2001).

  5. 5

    Ramstrom, O. & Lehn, J.M. Drug discovery by dynamic combinatorial libraries. Nat. Rev. Drug Disc. 1, 26–32 (2002).

  6. 6

    Lewis, W.G. et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem. Int. Edn. Engl. 41, 1053–1057 (2002).

  7. 7

    Rowan, S.J., Cantrill, S.J., Cousins, G.R.L., Sanders, J.K.M. & Stoddart, J.F. Dynamic covalent chemistry. Angew. Chem. Int. Edn. Engl. 41, 898–952 (2002).

  8. 8

    Erlanson, D. et al. Site-directed ligand discovery. Proc. Natl. Acad. Sci. USA 97, 9367–9372 (2000).

  9. 9

    Shuker, S.B., Hajduk, P.J., Meadows, R.P. & Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531–1534 (1996).

  10. 10

    Thornberry, N.A. et al. A combinatorial approach defines specificities of members of the caspase family and Granzyme B. J. Biol. Chem. 272, 17907–17911 (1997).

  11. 11

    Rano, T.A. et al. A combinatorial approach for determining protease specificities: application to interleukin-1β converting enzyme. Chem. Biol. 4, 149–155 (1997).

  12. 12

    Kaufmann, S.H. & Hengartner, M.O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 11, 526–534 (2001).

  13. 13

    Utz, P. & Anderson, P. Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ. 7, 589–602 (2000).

  14. 14

    Hengartner, M.O. The biochemistry of apoptosis. Nature 407, 770–776 (2000).

  15. 15

    Gervais, F. et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-β precursor protein and amyloidogenic Aβ peptide formation. Cell 97, 395–406 (1999).

  16. 16

    Hotchkiss, R.S. et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1, 496–501 (2000).

  17. 17

    McBride, C., McPhail, L. & Steeves, J. Emerging therapeutic targets in caspase-dependent disease. Emerg. Therapeutic Targets 3, 391–411 (1999).

  18. 18

    Yue, T.-L., Ohlstein, E. & Ruffolo, R. Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases. Curr. Opin. Chem. Biol. 3, 474–480 (1999).

  19. 19

    Nicholson, D. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810–816 (2000).

  20. 20

    Lee, D. et al. Potent and selective nonpeptide inhibitors of caspases-3 and -7 inhibit apoptosis and maintain cell functionality. J. Biol. Chem. 275, 16007–16014 (2000).

  21. 21

    Han, B. et al. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxia-ischemic brain injury. J. Biol. Chem. 277, 30128–30136 (2002).

  22. 22

    Dolle, R.E. et al. P1 aspartate-based peptide α-((2,6-dichlorobenzoyl)oxy)methyl ketones as potent time-dependent inhibitors of interleukin-1β converting enzyme. J. Med. Chem. 37, 563–564 (1994).

  23. 23

    Arkin, M. et al. Binding of small molecules to an adaptive protein:protein interface. Proc. Natl. Acad. Sci. USA, in press (2003).

  24. 24

    Mittl, P.R.E. et al. Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-asp-val-ala-asp fluoromethyl ketone. J. Biol. Chem. 272, 6539–6547 (1997).

  25. 25

    Margolin, N. et al. Substrate and inhibitor specificity of interleukin-1β-converting enzyme and related caspases. J. Biol. Chem. 272, 7223–7228 (1997).

  26. 26

    Garcia-Calvo, M. et al. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273, 32608–32613 (1998).

  27. 27

    Slee, E.A., Adrain, C. & Martin, S.J. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 276, 7320–7326 (2001).

  28. 28

    Fry, D.W. et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95, 12022–12027 (1998).

  29. 29

    Tsou, H.R. et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 44, 2719–2734 (2001).

  30. 30

    Myers, J.K. & Widlanski, T.S. Mechanism-based inactivation of prostatic acid phosphatase. Science 262, 1451–1453 (1993).

  31. 31

    Taylor, W.P., Zhang, Z.Y. & Widlanski, T.S. Quiescent affinity inactivators of protein tyrosine phosphatases. Bioorg. Med. Chem. 4, 1515–1520 (1996).

  32. 32

    Ham, S.W., Park, J., Lee, S.J. & Yoo, J.S. Selective inactivation of protein tyrosine phosphatase PTP1B by sulfone analogue of naphthoquinone. Bioorg. Med. Chem. Lett. 9, 185–186 (1999).

  33. 33

    Arabaci, G., Xiao-Chuan, G., Beebe, K.D., Coggeshall, K.M. & Pei, D. α-Haloacetophenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J. Am. Chem. Soc. 121, 5085–5086 (1999).

  34. 34

    Carter, P.H. et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α. Proc. Natl. Acad. Sci. USA 98, 11879–11884. (2001).

  35. 35

    Choong, I.C. et al. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based design. J. Med. Chem. 45, 5005–5022 (2002).

  36. 36

    Thornberry, N.A. et al. Inactivation of interleukin-1β converting enzyme by peptide (acyloxy)methyl ketones. Biochemistry 33, 3934–3940 (1994).

  37. 37

    Pflugrath, J.W. The finer things in X-ray diffraction data collection. Acta Crystallogr. D 55, 1718–1725 (1999).

  38. 38

    Navaza, J. AMORE—an automated package for molecular replacement. Acta Crystallogr. A 50, 157–163 (1994).

  39. 39

    Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110–119 (1991).

Download references

Acknowledgements

This research was supported in part by SBIR grant no. 2 R44 CA 85141-03. We thank the staff at SSRL beamline 7.1 for assistance with data collection; Andrew C. Braisted, Darren R. Raphael, and Jeff Jacobs for monophore synthesis; the automation group (Stuart Lam, Thomas Webb, and Alex Hsi) for their help in preparatory HPLC purifications; Simone Evarts and Mark Cancilla for HRMS determinations; James A. Wells for helpful discussions; Jennifer Wilkinson for tissue culture assistance; and Monya L. Baker, Willard Lew, and Robert S. McDowell for critical readings of the manuscript.

Author information

Correspondence to Daniel A. Erlanson or Tom O'Brien.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Erlanson, D., Lam, J., Wiesmann, C. et al. In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol 21, 308–314 (2003). https://doi.org/10.1038/nbt786

Download citation

Further reading